Objectives: Exosomes are small extracellular vesicles ranging from 30-150 nm in diameter, playing a crucial role in cell communication, tissue repair, and regeneration. In these collective studies an innovative therapy method based on Platelet Rich Plasma (PRP) to induce the release of billions of vesicles by stressing platelets and other blood cells within PRP. Through a specialized protocol and devices, this method enhances platelet activation, providing a plasma rich in exosomes derived from platelets. This approach finds extensive applications in aesthetic, medical and therapeutic treatments.
Introduction: This study aims to develop a PRP variant targeted for aesthetic and medical applications. The treatment method delivers effective outcomes in various areas such as skin regeneration and hair loss. Notably, this method is entirely autologous, utilizing exosomes derived from the patient's own platelets. This approach ensures safety by being closed to horizontal gene transfer, thereby eliminating the risk of immune reactions or other complications associated with foreign biological materials. Additionally, the final milieu is fully injectable for the use of clinical applications.
Materials / method: Using the Microlyzer 600µm (T-LAB – Turkey), blades were employed to stress the cells, inducing the secretion of billions of vesicles and promoting platelet activation. The shear stress created by the device applied mechanical forces to the platelets, leading to their activation and subsequent exosome production. An Advanced PRX Tube was used to further facilitate the secretion of billions of vesicles by cells and the activation of platelets. This tube generated vortices through varying G-forces, continuing the activation process.The protocol steps ensured the release of production of EVs.
Results: Laboratory findings confirm that this autologus exosome method achieves 4.5×10^9 particles/mL of vesicles, with an average vesicle size of 116.6 nm. This particle count is significantly higher than that of most exosome products currently available on the market, indicating the superior efficacy of our method. Analysis of CD markers reveals: CD9: 99.6%, CD45: 0.3%, CD41: 99.4%, CD61: 98.6%, CD81 : 98.5%, Viability: 98.9%. The results regarding less presence of leukocytes and high presence of plt-derived EVs reinforces the purity and targeted effectiveness of our method.
Conclusion: The results obtained with autologous plt-derived exosomes rich plasma offers higher yielded exosomes content within the finally characterized milieu. Due to its nature, apart from widely offered different source of exosome alternatives, autologous platelet-derived exosomes rich plasma technique poses no risk of allergic reactions post-injection, making it a safe and effective treatment option in aesthetic and medical applications.
利益冲突声明
您有否接受任何资金来支持研究这个主题？
否
您是否接受过关于这项研究的任何酬金或其他报酬？
否
你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: T-LAB, Founder
你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
